Evolus (NASDAQ:EOLS) Price Target Lowered to $13.00 at BTIG Research

Evolus (NASDAQ:EOLS) had its price target decreased by BTIG Research from $18.00 to $13.00 in a report released on Thursday, MarketBeat.com reports. BTIG Research currently has a buy rating on the stock.

EOLS has been the topic of a number of other research reports. Mizuho dropped their target price on Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Evolus in a research note on Friday, January 9th. Stifel Nicolaus cut their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Finally, Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Evolus Stock Performance

Shares of NASDAQ:EOLS opened at $5.08 on Thursday. Evolus has a one year low of $4.74 and a one year high of $17.12. The stock has a market capitalization of $329.29 million, a price-to-earnings ratio of -5.52 and a beta of 0.91. The company has a 50-day simple moving average of $6.50 and a 200-day simple moving average of $7.05.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $68.97 million for the quarter, compared to analysts’ expectations of $91.23 million. As a group, research analysts forecast that Evolus will post -0.61 EPS for the current fiscal year.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $75,353.85. Following the transaction, the insider directly owned 354,388 shares of the company’s stock, valued at $2,533,874.20. This represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by company insiders.

Institutional Trading of Evolus

Institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. purchased a new position in Evolus in the second quarter valued at about $22,431,000. Nantahala Capital Management LLC boosted its stake in shares of Evolus by 33.2% during the 3rd quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock worth $35,163,000 after acquiring an additional 1,428,931 shares in the last quarter. Soleus Capital Management L.P. grew its holdings in shares of Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after acquiring an additional 1,039,842 shares during the period. Caligan Partners LP increased its stake in Evolus by 23.8% in the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares in the last quarter. Finally, Pinnacle Associates Ltd. purchased a new position in Evolus in the 2nd quarter valued at approximately $6,318,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.